|
🐜
|
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
106 auth.
E. Cohen,
D. Soulières,
C. Tourneau,
J. Dinis,
L. Licitra,
M. Ahn,
A. Soria,
J. Machiels,
N. Mach,
R. Mehra,
B. Burtness,
Pingye Zhang,
Jonathan C Cheng,
R. Swaby,
K. Harrington,
...
M. Acosta-Rivera,
D. Adkins,
M. Aghmesheh,
M. Airoldi,
E. Aleknavičius,
Y. Al-farhat,
A. Algazi,
S. Almokadem,
A. Alyasova,
J. Bauman,
M. Benasso,
A. Berrocal,
V. Bray,
B. Burtness,
F. Caponigro,
A. Castro,
T. Cescon,
Kelvin K. W. Chan,
A. Chaudhry,
B. Chauffert,
E. Cohen,
T. Csőszi,
J. Boer,
J. Delord,
A. Dietz,
J. Dinis,
C. Dupuis,
L. Digue,
J. Erfán,
Y. E. Álvarez,
M. Evans,
M. Fidler,
M. Forster,
S. Friesland,
A. Ganti,
L. Geoffrois,
C. Grant,
V. Gruenwald,
K. Harrington,
T. Hoffmann,
G. Horvai,
A. Inčiūra,
R. Jang,
P. Jankowska,
A. Jimeno,
M. Joseph,
A. Ramiro,
B. Karaszewska,
A. Kawecki,
U. Keilholz,
U. Keller,
Sung-Bae Kim,
J. Kocsis,
N. Kotecki,
M. Kozloff,
J. Lambea,
L. Landherr,
Yuri Lantsukhay,
S. Lazarev,
Lip W Lee,
Igor Lifirenko,
D. Martincic,
O. V. Matorin,
M. McGrath,
K. Misiukiewicz,
J. Morris,
F. F. Mufazalov,
J. Niu,
D. Srinivasan,
P. Segura,
D. Rauch,
Maria Leonor Ribeiro,
C. Rodriguez,
F. Rolland,
A. Russo,
Á. Ruzsa,
Frederico Sanches,
S. Shin,
Mikhail Shtiveland,
D. Soulières,
P. Specenier,
É. Szekanecz,
J. Szota,
C. Herpen,
Héctor A. Vélez‐Cortés,
W. Walsh,
S. Wilop,
R. Winterhalder,
M. Wojtukiewicz,
D. Wong,
D. Zandberg
|
10 |
2019 |
10
🐜
|
|
🐜
|
Assessment of the Evolution of Cancer Treatment Therapies
7 auth.
M. Arruebo,
N. Vilaboa,
Berta Sáez-Gutiérrez,
J. Lambea,
A. Trés,
M. Valladares,
...
Á. González-Fernández
|
9 |
2011 |
9
🐜
|
|
🐜
|
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer
56 auth.
S. Stacey,
A. Manolescu,
P. Sulem,
S. Thorlacius,
S. A. Gudjonsson,
Gudbjorn F. Jonsson,
Margret Jakobsdottir,
J. Bergthorsson,
J. Gudmundsson,
K. Aben,
L. Strobbe,
D. Swinkels,
K. C. van Engelenburg,
B. Henderson,
L. Kolonel,
...
L. Le Marchand,
E. Millastre,
R. Andrés,
B. Saez,
J. Lambea,
J. Godino,
E. Polo,
A. Trés,
S. Picelli,
Johanna Rantala,
S. Margolin,
T. Jónsson,
H. Sigurdsson,
Thora Jonsdottir,
J. Hrafnkelsson,
J. Jóhannsson,
T. Sveinsson,
Gardar Myrdal,
H. N. Grimsson,
S. Sveinsdottir,
K. Alexíusdóttir,
J. Saemundsdottir,
A. Sigurdsson,
J. Kostic,
L. Gudmundsson,
K. Kristjánsson,
G. Másson,
J. Fackenthal,
C. Adebamowo,
T. Ogundiran,
O. Olopade,
C. Haiman,
A. Lindblom,
J. Mayordomo,
L. Kiemeney,
J. Gulcher,
T. Rafnar,
U. Thorsteinsdóttir,
O. Johannsson,
A. Kong,
K. Stefánsson
|
8 |
2008 |
8
🐜
|
|
🐜
|
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action
10 auth.
I. Durán,
J. Lambea,
P. Maroto,
J. González-Larriba,
L. Flores,
S. Granados-Principal,
...
M. Graupera,
B. Saez,
A. Vivancos,
O. Casanovas
|
6 |
2017 |
6
🐜
|
|
🐜
|
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment
9 auth.
J. Martínez-Trufero,
Dolores Isla,
J. C. Adansa,
A. Irigoyen,
R. Hitt,
I. Gil-Arnáiz,
...
J. Lambea,
M. J. Lecumberri,
J. J. Cruz
|
5 |
2010 |
5
🐜
|
|
🐜
|
Dendritic cell uptake of iron‐based magnetic nanoparticles
12 auth.
Gerardo F. Goya,
I. Marcos-Campos,
R. Fernandez-Pacheco,
Berta Saez,
Javier Godino,
L. Asín,
...
J. Lambea,
P. Tabuenca,
J. Mayordomo,
Luis Larrad,
M. R. Ibarra,
Alejandro Tres
|
5 |
2008 |
5
🐜
|
|
🐜
|
Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
11 auth.
R. Andrés,
J. Mayordomo,
R. Lara,
R. Lastra,
E. Ortega,
E. Polo,
...
J. Lambea,
D. Isla,
A. Saenz-Cusi,
P. Escudero,
A. Trés
|
4 |
2005 |
4
🐜
|
|
🐜
|
Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
13 auth.
M. Méndez-Vidal,
A. Molina,
U. Anido,
I. Chirivella,
O. Etxaniz,
E. Fernández-Parra,
M. Guix,
C. Hernández,
J. Lambea,
Á. Montesa,
...
Á. Pinto,
S. Ros,
E. Gallardo
|
4 |
2018 |
4
🐜
|
|
🐜
|
GLIM vs ESPEN criteria for the diagnosis of early malnutrition in oncological outpatients.
11 auth.
M. Gascón-Ruiz,
D. Casas-Deza,
I. Torres-Ramón,
M. Zapata-García,
N. Alonso,
A. Sesma,
...
J. Lambea,
M. Álvarez-Alejandro,
E. Quílez,
D. Isla,
J. Arbonés-Mainar
|
4 |
2021 |
4
🐜
|
|
🐜
|
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
22 auth.
J. Puente,
N. Laínez,
M. Dueñas,
M. Méndez-Vidal,
E. Esteban,
D. Castellano,
M. Martínez-Fernández,
L. Basterretxea,
María José Juan-Fita,
L. Antón,
...
L. León,
J. Lambea,
B. Pérez-Valderrama,
S. Vázquez,
C. Suarez,
X. G. del Muro,
E. Gallardo,
J. P. Maroto,
M. L. Samaniego,
Beatriz Suárez-Paniagua,
J. Sanz,
J. Paramio
|
4 |
2017 |
4
🐜
|
|
🦁
|
Quality of life and supportive care for patients with metastatic renal cell carcinoma
8 auth.
J. Lambea,
C. Hinojo,
N. Laínez,
M. Lázaro,
L. León,
Angel A. Rodriguez,
...
D. S. Prado,
E. Esteban
|
4 |
2012 |
4
🦁
|
